AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Autolus Therapeutics plc American Depositary Share Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Autolus Therapeutics announced it has released its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) that it will use in a conference call; both exhibits are expressly noted as furnished rather than filed.

The 8-K clarifies that the information in the exhibits is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically stated. The form text does not include the underlying financial tables, revenue, expense or cash metrics, so detailed figures and operational commentary must be obtained from the attached Exhibit 99.1 and Exhibit 99.2.

Autolus Therapeutics ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. La società ha fornito un comunicato stampa (Allegato 99.1) e una presentazione aziendale aggiornata (Allegato 99.2) che utilizzerà in una conference call; entrambi gli allegati sono espressamente indicati come furnished e non come filed.

L'8-K precisa che le informazioni contenute negli allegati non sono soggette alle responsabilità previste dalla Sezione 18 e non vengono incorporate per riferimento in altri documenti a meno che non sia specificato. Il testo del modulo non include le tabelle finanziarie sottostanti, né i dati su ricavi, costi o liquidità, pertanto cifre dettagliate e commenti operativi devono essere desunti dagli Allegati 99.1 e 99.2 allegati.

Autolus Therapeutics anunció que ha publicado sus resultados financieros correspondientes al trimestre cerrado el 30 de junio de 2025 y ofreció una actualización corporativa. La compañía presentó un comunicado de prensa (Exhibición 99.1) y una presentación corporativa actualizada (Exhibición 99.2) que empleará en una conferencia telefónica; ambas exhibiciones se indican expresamente como furnished y no como filed.

El formulario 8-K aclara que la información de las exhibiciones no está sujeta a las responsabilidades de la Sección 18 y no se incorpora por referencia a otros documentos salvo que se indique específicamente. El texto del formulario no incluye las tablas financieras subyacentes, ni los datos de ingresos, gastos o efectivo, por lo que las cifras detalladas y los comentarios operativos deben consultarse en las Exhibiciones 99.1 y 99.2 adjuntas.

Autolus TherapeuticsëŠ� 2025ë…� 6ì›� 30ì�ë¡� 종료ë� 분기 실ì ì� 발표하고 기업 ì—…ë°ì´íЏë¥� 제공했다ê³� ë°í˜”습니ë‹�. 회사ëŠ� ë³´ë„ìžë£Œ(Exhibit 99.1)와 향후 컨í¼ëŸ°ìФ 콜ì—ì„� 사용í•� ì—…ë°ì´íЏë� 기업 프레젠테ì´ì…˜(Exhibit 99.2)ì� 제공했으ë©�, ë‘� 전시ë¬� ëª¨ë‘ ëª…ì‹œì ìœ¼ë¡� furnishedë¡� 표기ë˜ì–´ filedê°€ 아님ì� 명확íž� 했습니다.

해당 8-KëŠ� ì „ì‹œë¬¼ì˜ ì •ë³´ê°€ Section 18ì—� 따른 ì±…ìž„ 대ìƒì´ 아니ë©�, 명시ì ìœ¼ë¡� 언급ë˜ì§€ 않는 í•� 다른 제출서류ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않는다고 명시합니ë‹�. ì–‘ì‹ ë³¸ë¬¸ì—는 기초 재무í‘�, 수ìµÂ·ë¹„ìš© ë˜ëŠ” 현금 지표가 í¬í•¨ë˜ì–´ 있지 않으므ë¡� ìƒì„¸ 수치와 ìš´ì˜ ê´€ë � ì„¤ëª…ì€ ì²¨ë¶€ë� Exhibit 99.1 ë°� Exhibit 99.2ì—서 확ì¸í•´ì•¼ 합니ë‹�.

Autolus Therapeutics a annoncé la publication de ses résultats financiers pour le trimestre clos le 30 juin 2025 et a communiqué une mise à jour corporate. La société a fourni un communiqué de presse (Exhibit 99.1) et une présentation corporate actualisée (Exhibit 99.2) qu’elle utilisera lors d’une conférence téléphonique ; les deux pièces sont expressément indiquées comme furnished et non comme filed.

Le formulaire 8‑K précise que les informations contenues dans ces pièces ne sont pas soumises aux responsabilités prévues par la Section 18 et ne sont pas incorporées par renvoi dans d’autres dépôts sauf indication expresse. Le texte du formulaire n’inclut pas les tableaux financiers sous-jacents, ni les chiffres de revenus, de charges ou de trésorerie ; les données détaillées et les commentaires opérationnels doivent donc être consultés dans les Exhibit 99.1 et 99.2 joints.

Autolus Therapeutics gab bekannt, dass es die Finanzergebnisse für das zum 30. Juni 2025 endende Quartal veröffentlicht und ein Unternehmensupdate bereitgestellt hat. Das Unternehmen legte eine Pressemitteilung (Exhibit 99.1) und eine aktualisierte Unternehmenspräsentation (Exhibit 99.2) vor, die in einer Telefonkonferenz verwendet werden sollen; beide Anhänge werden ausdrücklich als furnished und nicht als filed bezeichnet.

Das Formblatt 8-K stellt klar, dass die Informationen in den Anhängen nicht den Haftungsbestimmungen von Section 18 unterliegen und nicht in andere Einreichungen durch Verweis aufgenommen werden, es sei denn, dies wird ausdrücklich angegeben. Der Formtext enthält nicht die zugrunde liegenden Finanztabellen sowie keine Angaben zu Umsatz, Aufwand oder Cash-Kennzahlen, sodass detaillierte Zahlen und operative Erläuterungen den beigefügten Exhibits 99.1 und 99.2 entnommen werden müssen.

Positive
  • Quarterly results and corporate update announced, indicating timely communication of company performance
  • Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2) furnished for the conference call, improving investor access to materials
Negative
  • The 8-K does not include financial metrics or operational tables; detailed figures are only in the furnished exhibits
  • Materials are furnished, not filed, which limits Section 18 liability and means the 8-K text is not incorporated by reference into other filings unless explicitly stated

Insights

TL;DR: Routine earnings disclosure furnished via press release and presentation; 8-K contains no financial line items.

The filing signals that Autolus has released quarterly results and a corporate presentation, which supports transparency around near-term performance. Because the materials are "furnished" and not "filed," the 8-K text itself provides limited analytical value: it confirms the event and points to exhibits for substance. Analysts should review Exhibit 99.1 and 99.2 for revenue, expense, cash position and any management commentary before adjusting models.

TL;DR: Standard Regulation FD and results disclosure; furnishing limits Section 18 liability but fulfills disclosure obligations.

From a disclosure controls perspective, the company followed common practice by furnishing the press release and presentation and by stating the exhibits are not incorporated by reference. This protects against certain post-filing liabilities while ensuring investors receive the information. The 8-K lists exhibits clearly but does not itself provide the substantive metrics, so governance and compliance teams have met procedural requirements but stakeholders must access the exhibits for full disclosure.

Autolus Therapeutics ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. La società ha fornito un comunicato stampa (Allegato 99.1) e una presentazione aziendale aggiornata (Allegato 99.2) che utilizzerà in una conference call; entrambi gli allegati sono espressamente indicati come furnished e non come filed.

L'8-K precisa che le informazioni contenute negli allegati non sono soggette alle responsabilità previste dalla Sezione 18 e non vengono incorporate per riferimento in altri documenti a meno che non sia specificato. Il testo del modulo non include le tabelle finanziarie sottostanti, né i dati su ricavi, costi o liquidità, pertanto cifre dettagliate e commenti operativi devono essere desunti dagli Allegati 99.1 e 99.2 allegati.

Autolus Therapeutics anunció que ha publicado sus resultados financieros correspondientes al trimestre cerrado el 30 de junio de 2025 y ofreció una actualización corporativa. La compañía presentó un comunicado de prensa (Exhibición 99.1) y una presentación corporativa actualizada (Exhibición 99.2) que empleará en una conferencia telefónica; ambas exhibiciones se indican expresamente como furnished y no como filed.

El formulario 8-K aclara que la información de las exhibiciones no está sujeta a las responsabilidades de la Sección 18 y no se incorpora por referencia a otros documentos salvo que se indique específicamente. El texto del formulario no incluye las tablas financieras subyacentes, ni los datos de ingresos, gastos o efectivo, por lo que las cifras detalladas y los comentarios operativos deben consultarse en las Exhibiciones 99.1 y 99.2 adjuntas.

Autolus TherapeuticsëŠ� 2025ë…� 6ì›� 30ì�ë¡� 종료ë� 분기 실ì ì� 발표하고 기업 ì—…ë°ì´íЏë¥� 제공했다ê³� ë°í˜”습니ë‹�. 회사ëŠ� ë³´ë„ìžë£Œ(Exhibit 99.1)와 향후 컨í¼ëŸ°ìФ 콜ì—ì„� 사용í•� ì—…ë°ì´íЏë� 기업 프레젠테ì´ì…˜(Exhibit 99.2)ì� 제공했으ë©�, ë‘� 전시ë¬� ëª¨ë‘ ëª…ì‹œì ìœ¼ë¡� furnishedë¡� 표기ë˜ì–´ filedê°€ 아님ì� 명확íž� 했습니다.

해당 8-KëŠ� ì „ì‹œë¬¼ì˜ ì •ë³´ê°€ Section 18ì—� 따른 ì±…ìž„ 대ìƒì´ 아니ë©�, 명시ì ìœ¼ë¡� 언급ë˜ì§€ 않는 í•� 다른 제출서류ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않는다고 명시합니ë‹�. ì–‘ì‹ ë³¸ë¬¸ì—는 기초 재무í‘�, 수ìµÂ·ë¹„ìš© ë˜ëŠ” 현금 지표가 í¬í•¨ë˜ì–´ 있지 않으므ë¡� ìƒì„¸ 수치와 ìš´ì˜ ê´€ë � ì„¤ëª…ì€ ì²¨ë¶€ë� Exhibit 99.1 ë°� Exhibit 99.2ì—서 확ì¸í•´ì•¼ 합니ë‹�.

Autolus Therapeutics a annoncé la publication de ses résultats financiers pour le trimestre clos le 30 juin 2025 et a communiqué une mise à jour corporate. La société a fourni un communiqué de presse (Exhibit 99.1) et une présentation corporate actualisée (Exhibit 99.2) qu’elle utilisera lors d’une conférence téléphonique ; les deux pièces sont expressément indiquées comme furnished et non comme filed.

Le formulaire 8‑K précise que les informations contenues dans ces pièces ne sont pas soumises aux responsabilités prévues par la Section 18 et ne sont pas incorporées par renvoi dans d’autres dépôts sauf indication expresse. Le texte du formulaire n’inclut pas les tableaux financiers sous-jacents, ni les chiffres de revenus, de charges ou de trésorerie ; les données détaillées et les commentaires opérationnels doivent donc être consultés dans les Exhibit 99.1 et 99.2 joints.

Autolus Therapeutics gab bekannt, dass es die Finanzergebnisse für das zum 30. Juni 2025 endende Quartal veröffentlicht und ein Unternehmensupdate bereitgestellt hat. Das Unternehmen legte eine Pressemitteilung (Exhibit 99.1) und eine aktualisierte Unternehmenspräsentation (Exhibit 99.2) vor, die in einer Telefonkonferenz verwendet werden sollen; beide Anhänge werden ausdrücklich als furnished und nicht als filed bezeichnet.

Das Formblatt 8-K stellt klar, dass die Informationen in den Anhängen nicht den Haftungsbestimmungen von Section 18 unterliegen und nicht in andere Einreichungen durch Verweis aufgenommen werden, es sei denn, dies wird ausdrücklich angegeben. Der Formtext enthält nicht die zugrunde liegenden Finanztabellen sowie keine Angaben zu Umsatz, Aufwand oder Cash-Kennzahlen, sodass detaillierte Zahlen und operative Erläuterungen den beigefügten Exhibits 99.1 und 99.2 entnommen werden müssen.

0001730463FALSE00017304632025-08-122025-08-120001730463sic:Z88802025-08-122025-08-120001730463us-gaap:CommonClassAMember2025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025
Autolus Therapeutics plc
(Exact name of registrant as specified in its Charter)

England and Wales
001-38547
Not applicable
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
The Mediaworks
191 Wood Lane
LondonW12 7FP
United Kingdom
(Address of principal executive offices)(Zip Code)
(44) 20
3829 6230
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share
AUTLThe Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share**
The Nasdaq Stock Market LLC*
*
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions.
On August 12, 2025, Autolus Therapeutics plc (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
In connection with its conference call on August 12, 2025 to discuss its results for the quarter ended June 30, 2025, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.




Item 9.01 Financial Statements and Exhibits
d) Exhibits
Exhibit No.Description of Exhibit
99.1
Press release dated August 12, 2025
99.2
Corporate Presentation dated August 12, 2025
104
Cover Page Interactive Date File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AUTOLUS THERAPEUTICS PLC
Dated: August 12, 2025By:/s/Christian Itin, Ph.D.
Name: Christian Itin, Ph.D.
Title: Chief Executive Officer



FAQ

What did Autolus (AUTL) disclose in this 8-K?

The company announced it released financial results for the quarter ended June 30, 2025 and provided a corporate update; a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) were furnished.

Where can I find the full financial results for AUTL?

The full financial figures and operational commentary are contained in the furnished Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation); the 8-K text does not include the tables.

Are the exhibits in this AUTL 8-K filed or furnished?

The filing states the press release and presentation are furnished, not filed, and therefore are not subject to Section 18 liabilities and are not incorporated by reference into other filings unless explicitly stated.

Which exhibits were included with the 8-K?

Exhibit 99.1 is the press release, Exhibit 99.2 is the updated corporate presentation, and Exhibit 104 is the Cover Page Interactive Data File.

Does the 8-K provide forward-looking guidance or detailed metrics?

No. The 8-K text does not include forward-looking guidance or detailed financial metrics; those items, if present, would be in the furnished exhibits.
AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Latest SEC Filings

AUTL Stock Data

614.78M
213.38M
18.09%
91.05%
5.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
United Kingdom
LONDON